Vladimir D. Ivanov
Saint Petersburg, SPE, Russian Federation
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Correction to: Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia in the phase 3 COMMODORE trial.
Journal: Annals of hematology
Published: February 11, 2026
Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia in the phase 3 COMMODORE trial.
Journal: Annals of hematology
Published: August 21, 2025
Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study.
Journal: Med (New York, N.Y.)
Published: April 16, 2025
The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia.
Journal: American journal of hematology
Published: July 11, 2024
Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia.
Journal: Future oncology (London, England)
Published: July 19, 2022
Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia.
Journal: American journal of hematology
Published: March 08, 2022
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia.
Journal: Blood cancer journal
Published: December 21, 2021
Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy.
Journal: Blood cancer journal
Published: October 27, 2021
Last Updated: 09/26/2026